These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34964909)

  • 21. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis.
    Mulkey F; Theoret MR; Keegan P; Pazdur R; Sridhara R
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32107275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma.
    Weng Z; Ertle J; Zheng S; Lauenstein T; Mueller S; Bockisch A; Gerken G; Yang D; Schlaak JF
    Oncol Lett; 2013 Dec; 6(6):1707-1712. PubMed ID: 24260066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
    Lencioni R; Montal R; Torres F; Park JW; Decaens T; Raoul JL; Kudo M; Chang C; Ríos J; Boige V; Assenat E; Kang YK; Lim HY; Walters I; Llovet JM
    J Hepatol; 2017 Jun; 66(6):1166-1172. PubMed ID: 28131794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
    Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response Evaluation Using Contrast-Enhanced Ultrasound for Unresectable Advanced Hepatocellular Carcinoma Treated With Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy.
    Zhao CK; Guan X; Pu YY; Zhou BY; Wang LF; Sun YK; Yin HH; Xia HS; Wang X; Han H; Xu HX
    Ultrasound Med Biol; 2024 Jan; 50(1):142-149. PubMed ID: 37852872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
    Takada J; Hidaka H; Nakazawa T; Kondo M; Numata K; Tanaka K; Matsunaga K; Okuse C; Kobayashi S; Morimoto M; Ohkawa S; Koizumi W
    BMC Res Notes; 2015 Oct; 8():609. PubMed ID: 26502722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization.
    Lee JS; Choi HJ; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baek SE; Chung YE; Park MS; Kim MJ; Rhee H; Kim SU
    Gut Liver; 2020 Nov; 14(6):765-774. PubMed ID: 32050313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
    Ichikawa T; Machida N; Sasaki H; Tenmoku A; Kaneko H; Negishi R; Oi I; Fujino MA
    Oncology; 2016; 91(6):317-330. PubMed ID: 27784014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
    Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma.
    Lim TS; Rhee H; Kim GM; Kim SU; Kim BK; Park JY; Ahn SH; Han KH; Choi JY; Kim DY
    J Vasc Interv Radiol; 2019 Aug; 30(8):1194-1200.e1. PubMed ID: 31235408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma.
    Seyal AR; Gonzalez-Guindalini FD; Arslanoglu A; Harmath CB; Lewandowski RJ; Salem R; Yaghmai V
    Hepatology; 2015 Oct; 62(4):1111-21. PubMed ID: 25999236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
    Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J
    Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial.
    Ahmed FS; Dercle L; Goldmacher GV; Yang H; Connors D; Tang Y; Karovic S; Zhao B; Carvajal RD; Robert C; Maitland ML; Oxnard GR; Schwartz LH
    Eur Radiol; 2021 Apr; 31(4):1853-1862. PubMed ID: 32995974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma.
    Chen Q; Wang J; Wang X; Yin Y; Wang X; Song Z; Xing B; Li Y; Zhang J; Qin J; Jiang R
    Clin Lung Cancer; 2024 Jan; 25(1):29-38. PubMed ID: 38008641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria.
    Ghosn M; Derbel H; Kharrat R; Oubaya N; Mulé S; Chalaye J; Regnault H; Amaddeo G; Itti E; Luciani A; Kobeiter H; Tacher V
    Diagn Interv Imaging; 2021 Jan; 102(1):35-44. PubMed ID: 33012693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.
    Salvaggio G; Furlan A; Agnello F; Cabibbo G; Marin D; Giannitrapani L; Genco C; Midiri M; Lagalla R; Brancatelli G
    Radiol Med; 2014 Apr; 119(4):215-21. PubMed ID: 24297581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
    Wang W; Bai W; Wang E; Zhao Y; Liu L; Yang M; Cai H; Xia D; Zhang L; Niu J; Yin Z; Zhang Z; Fan D; Xia J; Han G
    Int J Cancer; 2017 Jan; 140(2):390-399. PubMed ID: 27681592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice.
    Rimola J; Da Fonseca LG; Sapena V; Perelló C; Guerrero A; Simó MT; Pons M; De La Torre-Aláez M; Márquez L; Calleja JL; Lledó JL; Varela M; Mínguez B; Sangro B; Matilla A; Torres F; Ayuso C; Bruix J; Reig M
    Eur J Radiol; 2021 Feb; 135():109484. PubMed ID: 33383399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation?
    Liu Q; Li A; Sun S; Luo R; Chen F
    J BUON; 2014; 19(2):398-405. PubMed ID: 24965398
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.